Cancer Treatment Costs Reduced

Government Intervention to Reduce Cancer Treatment Costs

The Union government has decided to cap trade margins at 30% of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs, aiming to make cancer treatment more affordable and reduce patients' out-of-pocket expenditure.

The measure will cover branded and generic drugs, domestically manufactured and imported medicines, and patented and non-patented products. An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be brought under the measure.

Background and Context

Cancer treatment is a significant financial burden for patients in India, with around 75% of the expenditure being borne out of pocket. The high cost of cancer medicines is a major contributor to this burden, making it essential for the government to intervene and regulate the prices.

Market Data Analysis

The National Pharmaceutical Pricing Authority (NPPA) analysed market data and found that the average trade mark-up on non-scheduled anti-cancer medicines was around 170%, with mark-ups reaching up to 700% in some cases. It also found substantial differences between prices charged through retail, hospital, and online pharmacies.

The government said the decision was prompted by the high financial burden of cancer treatment. Around 75% of cancer treatment expenditure is estimated to be borne out of pocket.

Cancer Medicines Market

The anti-cancer medicines market comprises around 225 drugs and 500 formulations, with an annual turnover of approximately ₹12,500 crore. Scheduled cancer medicines account for about ₹2,250 crore.

A senior official said that the government is drawing on the experience of a similar intervention in 2019, when the NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs by invoking its extraordinary powers under Paragraph 19 of the Drug Price Control Order, 2013.

The exercise had reportedly resulted in price reductions of up to 91%, with annual savings of ₹984 crore across 526 brands.

Expected Outcomes

The latest intervention is expected to result in price reductions of up to 70% of MRP and annual savings of around ₹2,500 crore, the government said.

Under the new framework, the trade margin will be capped at 30% of MRP, equivalent to 42.86% of the price to stockist.

“To ensure availability, manufacturers will be required to maintain their existing production level,” said the official.

The government said the measure would regulate trade margins rather than manufacturers’ selling prices or revenue, with the intervention aimed at reducing the margins retained across the distribution chain.

Read also: Leprosy in India: Challenges Ahead

Key Features of the Measure

• Capping trade margins at 30% of MRP for non-scheduled anti-cancer drugs
• Covering branded and generic drugs, domestically manufactured and imported medicines, and patented and non-patented products
• Regulating trade margins rather than manufacturers’ selling prices or revenue
• Aiming to reduce the margins retained across the distribution chain

₹2,500 crore in annual savings is expected from this measure, which will benefit 75% of cancer patients who bear the financial burden of treatment out of pocket.

Implications for Readers in India

The government's decision to cap trade margins on anti-cancer drugs is a significant step towards making cancer treatment more affordable for patients in India. With the expected annual savings of ₹2,500 crore, patients can hope to see a reduction in their out-of-pocket expenditure on cancer treatment.

What to Watch Next

The implementation of the trade margin cap and its impact on the prices of anti-cancer drugs will be closely watched. The government's efforts to regulate the pharmaceutical industry and make healthcare more affordable for citizens will continue to be a key area of focus.

Expert Perspective

Experts in the field of healthcare and pharmaceuticals have welcomed the government's decision, stating that it is a step in the right direction towards making cancer treatment more affordable. However, they also caution that the implementation of the measure will be crucial in determining its success.

Timeline of Events

The government's decision to cap trade margins on anti-cancer drugs is the latest in a series of measures aimed at regulating the pharmaceutical industry. The timeline of events is as follows:

• 2019: The NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs, resulting in price reductions of up to 91% and annual savings of ₹984 crore.
• 2023: The government decides to cap trade margins at 30% of MRP for all non-scheduled anti-cancer drugs, aiming to reduce cancer treatment costs and out-of-pocket expenditure for patients.

Background of Cancer Treatment in India

Cancer is a significant health concern in India, with the country reporting a high incidence of cancer cases. The financial burden of cancer treatment is a major challenge for patients, with many struggling to afford the high costs of treatment.

Government Initiatives to Reduce Healthcare Costs

The government has launched several initiatives to reduce healthcare costs and make healthcare more affordable for citizens. These initiatives include the capping of trade margins on pharmaceuticals, the implementation of the Ayushman Bharat scheme, and the launch of the National Health Mission.

Impact on the Pharmaceutical Industry

The capping of trade margins on anti-cancer drugs is expected to have a significant impact on the pharmaceutical industry. The measure is likely to lead to a reduction in the prices of anti-cancer drugs, making them more affordable for patients. However, it may also lead to a reduction in the revenue of pharmaceutical companies, which could have a negative impact on the industry.